Tg Therapeutics (TGTX) Total Current Liabilities (2010 - 2026)
Tg Therapeutics (TGTX) posted quarterly Total Current Liabilities of $187.1 million for Q1 2026, up 16.79% year-over-year from $160.2 million in Q1 2025, and up 21.69% quarter-over-quarter from $153.8 million in Q4 2025.
Tg Therapeutics (TGTX) Total Current Liabilities (2010 - 2026) Analysis & Trends
Tg Therapeutics' Total Current Liabilities history runs 17 years deep, the most recent figure standing at $187.1 million for Q1 2026.
- In Q1 2026, Total Current Liabilities rose 16.79% year-over-year to $187.1 million; the TTM figure through Mar 2026 stood at $187.1 million (up 16.79% YoY), while the FY2025 annual figure was $153.8 million, up 69.57% from the prior year.
- Total Current Liabilities for Q1 2026 stood at $187.1 million, up from $153.8 million in the prior quarter.
- The five-year high for Total Current Liabilities was $187.1 million in Q1 2026, with the low at $36.4 million in Q3 2022.
- The 5-year median for Total Current Liabilities is $90.7 million (2024), against an average of $99.3 million.
- The sharpest annual moves came in 2022 and 2024: Total Current Liabilities slumped 58.42% in 2022, then jumped 116.92% in 2024.
- Tg Therapeutics' Total Current Liabilities stood at $53.2 million in 2022, then advanced by 0.98% to $53.7 million in 2023, then jumped by 68.8% to $90.7 million in 2024, then soared by 69.57% to $153.8 million in 2025, then grew by 21.69% to $187.1 million in 2026.
- Business Quant data shows TGTX's Total Current Liabilities at $187.1 million in Q1 2026, $153.8 million in Q4 2025, and $156.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Tg Therapeutics | 7.46 Bn | 6.78 Bn | 199.14 Mn | 268.49 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 268.49 Mn |
| Mar 31, 2026 | 187.11 Mn |
| Dec 31, 2025 | 153.76 Mn |
| Sep 30, 2025 | 156.81 Mn |
| Jun 30, 2025 | 171.89 Mn |
| Mar 31, 2025 | 160.21 Mn |
| Dec 31, 2024 | 90.68 Mn |
| Sep 30, 2024 | 125.11 Mn |
| Jun 30, 2024 | 108.66 Mn |
| Mar 31, 2024 | 99.68 Mn |
| Dec 31, 2023 | 53.72 Mn |
| Sep 30, 2023 | 57.68 Mn |
| Jun 30, 2023 | 72.67 Mn |
| Mar 31, 2023 | 63.08 Mn |
| Dec 31, 2022 | 53.20 Mn |
| Sep 30, 2022 | 36.45 Mn |
| Jun 30, 2022 | 43.33 Mn |
| Mar 31, 2022 | 54.66 Mn |
| Dec 31, 2021 | 65.38 Mn |
| Sep 30, 2021 | 87.66 Mn |